Otilimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against granulocyte-macrophage colony-stimulating factor.
Trade Name |
|
Common Name |
Otilimab |
Indication |
|
Drug Class |
Monoclonal antibodies: immunomodulating |